Interpace Biosciences
(OTC) IDXG
Interpace Biosciences Financials at a Glance
Market Cap
$43.49M
Revenue (TTM)
$36.25M
Net Income (TTM)
$23.65M
EPS (TTM)
$0.73
P/E Ratio
2.14
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Price
$1.65
Volume
205
Open
$1.65
Price
$1.65
Volume
205
Open
$1.65
Previous Close
$1.65
Daily Range
$1.65 - $1.65
52-Week Range
$0.70 - $2.40
Estimated Earnings Date
Aug 12, 2026
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Price
$1.65
Volume
205
Open
$1.65
Previous Close
$1.65
Daily Range
$1.65 - $1.65
52-Week Range
$0.70 - $2.40
Estimated Earnings Date
Aug 12, 2026
IDXG News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Interpace Biosciences
Industry
Healthcare Providers and Services
Sector
Health CareEmployees
102
CEO
Thomas W. Burnell, PhD
Website
www.interpacediagnostics.comHeadquarters
Parsippany, NJ 07054, US
IDXG Financials
Key Financial Metrics (TTM)
Gross Margin
63%
Operating Margin
9%
Net Income Margin
65%
Return on Equity
214%
Return on Capital
11%
Return on Assets
71%
Earnings Yield
46.73%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$43.49M
Shares Outstanding
27.70M
Volume
205
Avg. Volume
6.24K
Financials (TTM)
Gross Profit
$24.13M
Operating Income
$4.08M
EBITDA
$4.76M
Operating Cash Flow
$5.83M
Capital Expenditure
-$356.00K
Free Cash Flow
$5.48M
Cash & ST Invst.
$2.51M
Total Debt
$1.18M
Interpace Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$9.03M
-21.6%
Gross Profit
$5.90M
-19.9%
Gross Margin
65.37%
N/A
Market Cap
$43.49M
N/A
Market Cap/Employee
$391.81K
N/A
Employees
111
N/A
Net Income
$721.00K
-56.2%
EBITDA
$1.35M
-33.9%
Quarterly Fundamentals
Total Cash
$2.65M
+121.3%
Total Debt
$1.08M
-74.5%
Accounts Receivable
$5.93M
-32.4%
Inventory
$961.00K
-20.5%
Long Term Debt
$635.00K
-41.2%
Short Term Debt
$445.00K
-85.9%
Return on Assets
70.79%
N/A
Return on Invested Capital
11.47%
N/A
Free Cash Flow
$142.00K
-88.5%
Operating Cash Flow
$283.00K
-77.1%